Luis E Raez, MD is an expert in Oncology at Sarasota Memorial Health Care System (United States). As of October 2026, ScienceLeadR ranks Luis E Raez in the top 1% of experts worldwide for Bronchial Neoplasms, Thoracic Neoplasms and Lung Neoplasms. Luis E Raez has authored 371 publications, the most recent in 2026, and is an investigator in 19 clinical trials, 1 of them ongoing. SLR score: 1,509 (community average: 125). How the SLR is computed.

LeadR Profile

Luis E Raez, MD Sarasota Memorial Health Care System United States
1 509 ScienceLeadR Reputation 1509
Network Map

Oncology

Subspecialties: Biochemistry - Pulmonology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Short Biography

Luis E. Raez, MD, FASCO, FACP, FCCP works as Chief Scientific Officer & Medical Director of the Memorial Cancer Institute (MCI)/Memorial Health Care System, He is Co-Director of the MCI/FAU Florida Cancer Center of Excellence designated by the Florida Department of Health, one of only six cancer centers in Florida. He is also Director of the Thoracic Oncology Program. He is also Clinical Professor of Medicine at Florida International University (FIU), Visiting Professor of Medicine at Cayetano Heredia University in Peru and Research Professor at Florida Atlantic University (FAU). He was the Vice-President of the Florida Society of Clinical Oncology (FLASCO) 2017-19 and President 2019-2021. He was an Associate Professor of Medicine, Epidemiology and Public Health, and a Co-Director of Thoracic Oncology at Sylvester Cancer Center/University of Miami for 10 years (2001-2011). He has expertise in medical oncology in the area of lung cancer, cancer disparities and liquid biopsies, He designs phase I-III clinical trials with new targeted agents and immunotherapy. Dr. Raez does translational research and clinical research. He has been funded by NCI and the pharma industry. He has given oral presentations and lectures in national and international meetings in the US, Europe, Latin-America, Africa and Asia. He has been the Chairman of the IASLC Latin American Group (LATAM) since 2018; Chair of the IASLC Membership Committee from 2015-2018; International Chair of the IASLC-Latin-American Meeting (LALCA) since 2014; Chairman for the "Miami Best of ASCO" since 2014, Chair and Founder of the "Miami Cancer Meeting (MCM)" since 2002, Co-Chairman at the "Puerto Rico Fall Cancer Symposia (FCS)" since 2010. He is one of the founder members of Oncology Latin-American Association (OLA). He is American Board Certified in: Internal Medicine and Medical Oncology. He is board eligible in Hematology. He is a member and serves in several committees at: AACR, OLA, ESMO, ASCO, IASLC, ALLIANCE, NCCTG, ACCP, ACP, ACSG, SLACOM, FLASCO among other institutions.

Organizations

Career arc: 1998 - 2026

Source: PubMed

Florida International University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 371

Citations

Citations: 17 887 1st author: 71 Last author: 75 Unique author: 3


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Real-World Outcomes of Fusion-Directed Targeted Therapy in Advanced Non-Small Cell Lung Cancer Harboring Actionable Gene Fusions.
PMID 42737745 — cells, genes, lung, progression-free survival, neoplasms, carcinoma, non-small-cell lung, gene fusion, lung neoplasms, small cell lung carcinoma, therapeutics
Int J Mol Sci20260
Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.
PMID 42532338 — research design, neoplasms, carcinoma, non-small-cell lung, uncertainty, therapeutics, rna
J Thorac Oncol20261
Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, and Bispecific Antibodies in Oncogene-Driven Non-Small-Cell Lung Cancer: Evolving Roles in Treatment Sequencing and Resistance Management.
PMID 42511594 — oncogenes, cells, lung, antibodies, pharmaceutical preparations, neoplasms, carcinoma, non-small-cell lung, biomarkers, central nervous system, lung neoplasms, small cell lung carcinoma, protein-tyrosine kinases, tyrosine, therapeutics, nervous system, antibodies, bispecific
Int J Mol Sci20260
The Evolving Role of Bispecific Antibodies in Oncogene-Driven NSCLC.
PMID 42512264 — oncogenes, antibodies, pharmaceutical preparations, neoplasms, carcinoma, non-small-cell lung, therapeutics, antibodies, bispecific
Cancers (Basel)20260
KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone.
PMID 42511798 — cells, lung, genes, ras, docetaxel, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, therapeutics, tumor microenvironment, drug resistance
Int J Mol Sci20265

Clinical Studies 19

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1 Study Chair: 5

By phase:

Phase 2 6
Phase 3 6
Phase 1/Phase 2 4
Phase 1 3

By status:

Completed 12
Active not recruiting 3
Recruiting 3
Terminated 1

By type:

Interventional 19

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 2
multicentric5to9 2
multicentricup10 11

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
NCT04919811 — cells, lung, safety, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, carcinoma
Phase 2Active not recruiting2021

LeadR Networks

Main global connection map